ABSTRACT
OBJECTIVE: To evaluate the evidence supporting vitamin C and D medication in the treatment and prevention of acute viral respiratory infectious disease, and to provide evidence for clinical rational medication and potential treatment option for COVID-19 especially. METHODS: PubMed database was retrieved from inception to February 13, 2020, and the references in the reviews and those not included in the database were manually retrieved. RESULTS: Eight literatures were included finally. In terms of COVID-19, MERS, and SARS, none literature about vitamin C and D medication was available. In terms of influenza, one prospective controlled trial proved vitamin C's efficacy. For vitamin D in influenza, one systematic review and one randomized controlled trial proved its efficacy, while three randomized controlled trials showed no efficacy. Additionally, one case-control study showed no statistical association between vitamin D level and the risk of influenza, and one randomized controlled trial showed no significant difference between high-dose and standard-dose vitamin D supplementation. CONCLUSION: Currently, no evidence supports the effectiveness of vitamin C and D medication in the prevention and treatment of COVID-19, MERS and SARS. However, limited evidence supports potential benefit of vitamin C and D medication in influenza. Physicians and pharmacists should take relevant clinical practice guidelines and supporting evidence into consideration when using vitamin C or D (especially high-dose medication), and pay attention to monitoring drug adverse reactions and drug interactions.
ABSTRACT
Ribavirin is a widely used nucleoside antiviral drug. During the epidemic of coronavirus disease 2019 (COVID-19), ribavirin was recommended for empirical treatment in the Clinical Management of Human Infection with COVID-19 (trial guidance v6). However, due to the large inter-individual variations in dose-response relationship, and extremely long terminal half time, it is necessary to perform therapeutic drug monitoring and individualized dose adjustment for ribavirin in special populations. In this article, the pharmacokinetics and therapeutic drug monitoring of ribavirin in different populations are reviewed in order to provide reference for clinical rational use and individualized medication of ribavirin for treatment of COVID-19. Copyright 2020 by the Chinese Pharmaceutical Association.
ABSTRACT
The coronavirus disease 2019 (COVID-19) outbreak is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) around the world, which has posed a great threat to global public health security. Angiotensin converting enzyme 2 (ACE2) has been identified as the major functional receptor of SARS-CoV-2, which plays an essential role in mediating virus invasion into host cells. Thus, an in-depth understanding of the recent progress of ACE2, its relationship with the virus and related drugs is of great significance for the prevention and treatment of COVID-19. Here, from the aspects of structure, expression and function, this article reviews the latest research progress of ACE2 and SARS-CoV-2. Meanwhile, this article also summarizes the mechanism of ACE2-mediated virus invasion and ACE2-related drugs, which will provide theoretical reference for viral prevention and treatment.
ABSTRACT
OBJECTIVE: To provide reference of donated drugs management for pharmaceutical departments during public health emergencies, so as to ensure the quality, safety and reasonable use of donated drugs. METHODS: Combined with the legal requirements and common problems of donated drugs, explore scientific and reasonable donated drug management principles, and establish donated drug management systems and processes. RESULTS: In the past, when medical institutions responded to major public health emergencies, there were some problems in the management of the demand, qualification and quality, validity, use, price, and surplus drugs of donated drugs. According to the requirements of the relevant laws, regulations and guidance on the characteristics, management, use and communication between donors and recipients of donated drugs, we established a scientific, reasonable and orderly management model, and clarified the management system, method and comprehensive management process. CONCLUSION: The problems, principles and models of donated drugs management were sorted out comprehensively, which is helpful to prevent and control of coronavirus disease 2019 (COVID-19).
ABSTRACT
OBJECTIVE: To systematically review the related guidelines of nutrition support therapy (hereinafter referred to as nutrition support) in acute respiratory disease, and to provide evidence-based evidences for clinical nutrition in coronavirus disease 2019 (COVID-19). METHODS: Retrieved from PubMed, EMBase, CNKI, etc., websites of association in nutrition and global guideline databases. The guidelines in nutrition support for related diseases were collected. Recommendations were summarized after data extraction and quality evaluation. RESULTS: A total of 10 guidelines were enrolled, with development time ranging from 2006 to 2019. There were 6 guidelines with quality of level A, 3 with level B, and 1 with level C. “scope and purpose”, “clarity” and “independence” showed the higher scores in AGREE Ⅱ, and “applicability” showed generally low scores. There were differences among emphases of guidelines, however, supplements for each other, and the recommendations for the same questions showed substantial agreement. CONCLUSION: The recommendations, in high quality guidelines of critical illness, acute respiratory distress syndrome, pneumonia, etc., could be applied to nutrition support in COVID-19.